ASCO 2019 | Induction regimens in NDMM: my clinical experience

During ASCO 2019, Chicago, US, Enrique M. Ocio, Marqués de Valdecilla University Hospital, Santander, ES, spoke to the MM Hub about the choice of induction regimens in newly diagnosed multiple myeloma (NDMM). The main focus of this interview is Enrique M. Ocio's clinical experience within Spain, and Europe.

The treatment of NDMM is split into transplant eligible (TE) and non-transplant eligible (NTE). In the TE patients, Enrique M. Ocio comments that bortezomib + thalidomide + dexamethasone (VTd) is the standard triplet used currently, though his preference would be to switch thalidomide to lenalidomide to reduce the rates of peripheral neuropathy associated with thalidomide. However, this is not currently approved by the European Medicines Agency (EMA), but it is hoped this will follow shortly. It was also noted that the incorporation of second generation proteasome inhibitors and monoclonal antibodies will further expand the options. In the NTE group, melphalan + prednisone + dexamethasone (MPD) is the standard, now with the option of addding daratumumab. Enrique M. Ocio concludes that we will shortly have numerous options to choose from in the NDMM setting, which will make clinical decisions difficult, but will be good news for the patients who will have more available therapies.

Enrique Ocio kindly gave his interview in Spanish, with the title: Regimenes de inducción en pacientes con MM de nuevo diagnóstico.